FDA has approved WestGene’s investigational new drug (IND) application for WGc-043, an Epstein-Barr virus (EBV)-related mRNA cancer vaccine in treating EBV-associated cancers.
WGc-043 offers new hope for patients battling advanced EBV-related cancers, which include nasopharyngeal carcinoma, natural killer T-cell lymphoma, and various other cancers of the stomach, lung, breast, liver, esophagus, and cervix.
Early data from investigator-initiated trials suggested that WGc-043 demonstrated promising efficacy and tolerability compared to other mRNA cancer vaccines.
Additionally, WGc-043 has shown broad applicability across various EBV-associated cancers and may offer advantages in terms of scalability and cost-effectiveness.
The FDA’s IND approval of WGc-043 was a critical step before a drug can be tested in humans. WestGene planned to initiate clinical trials to further evaluate the safety and efficacy of WGc-043 for treating EBV-related cancers.
Source: WestGene’s mRNA therapeutic cancer vaccine receives FDA approval
https://tinyurl.com/32xvxa36
